ChromaDex names Brianna Gerber CFO effective Jan 1, 2023; salary $325K

Niagen Bioscience, Inc.

Brianna Gerber appointed CFO after serving as interim CFO since August 2022.
Base salary $325,000; discretionary target bonus 50% of base; LTI opportunity 70% of base (Black-Scholes).
Termination w/o cause/good reason: 12-mo salary continuation, pro-rata bonus, COBRA (12 mos), accelerated vesting.
CEO Fried highlights her role in shepherding ChromaDex to EBITDA positive business with fiscal responsibility.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Brianna Gerber

Chief Financial Officer

NAGE · Niagen Bioscience, Inc.

Effective: 2023-01-01
Filed: January 5, 2023, 6:59 PM ET

appointed Brianna Gerber as Chief Financial Officer of the Company, effective as of January 1, 2023.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Brianna Gerber was appointed as Chief Financial Officer at Niagen Bioscience, Inc..

Action: appointed
Role: Chief Financial Officer

Exact text from the filing

appointed Brianna Gerber as Chief Financial Officer of the Company, effective as of January 1, 2023.

View on SEC.gov

Niagen Bioscience, Inc. filing history →

Source: SEC EDGAR

accession 0001628280-23-000381

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.